2024-03-29T01:59:14Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/48162024-02-01T12:09:57Zcom_20.500.12105_2053com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2054
00925njm 22002777a 4500
dc
Dierssen-Sotos, Trinidad
author
Gómez-Acebo, Inés
author
de Pedro, María
author
Perez-Gomez, Beatriz
author
Servitja, Sonia
author
Moreno, Víctor
author
Amiano, Pilar
author
Fernandez-Villa, Tania
author
Barricarte, Aurelio
author
Tardón, Adonina
author
Diaz-Santos, Marian
author
Peiro-Perez, Rosana
author
Marcos-Gragera, Rafael
author
Lope Carvajal, Virginia
author
Gràcia-Lavedan, Esther
author
Alonso, M. Henar
author
Michelena-Echeveste, Maria Jesus
author
Garcia-Palomo, Andrés
author
Guevara, Marcela
author
Castaño-Vinyals, Gemma
author
Aragones, Nuria
author
Kogevinas, Manolis
author
Pollan-Santamaria, Marina
author
Llorca, Javier
author
2016-08-20
BACKGROUND: The relationship between non-steroidal antiinflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors).
METHODS: In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics.
RESULTS:
In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers.
CONCLUSION:
Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers.
BMC Cancer. 2016; 16: 660
http://hdl.handle.net/20.500.12105/4816
27542890
10.1186/s12885-016-2692-4
1471-2407
BMC Cancer
Breast cancer
Non-steroidal anti-inflammatory drug
Hormone receptor positive breast cancer
HER2 positive breast cancer
Triple negative breast cancer
Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study